---
title: "Attovia Therapeutics to Participate in Upcoming Investor Conferences"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297954909.md"
description: "Attovia Therapeutics, Inc., based in San Carlos, California, disclosed on September 3, 2026, that the clinical-stage biopharmaceutical company, known as Attovia (Nasdaq: ATTO), is focusing on developing advanced biotherapeutics for immune-mediated diseases that have a significant lack of effective treatments. The company's management is set to take part in several investor conferences."
datetime: "2026-09-03T20:07:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297954909.md)
  - [en](https://longbridge.com/en/news/297954909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297954909.md)
generator: "portal-rs"
---

# Attovia Therapeutics to Participate in Upcoming Investor Conferences

Attovia Therapeutics, Inc., based in San Carlos, California, disclosed on September 3, 2026, that the clinical-stage biopharmaceutical company, known as Attovia (Nasdaq: ATTO), is focusing on developing advanced biotherapeutics for immune-mediated diseases that have a significant lack of effective treatments. The company's management is set to take part in several investor conferences.

### Related Stocks

- [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md)

## Related News & Research

- [Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27](https://longbridge.com/en/news/297941843.md)
- [Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash Runway](https://longbridge.com/en/news/297940103.md)
- [Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End  on September 14th](https://longbridge.com/en/news/298168859.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Vivani Medical Announces Participation in Upcoming Investor Conferences | VANI Stock News](https://longbridge.com/en/news/297953283.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**